Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_provenance.
- NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_assertion description "[Over-expression of ERBB2, a member of the family of transmembrane receptor tyrosine kinases, occurs in 15-30% of primary breast tumors and is associated with poor prognosis and chemoresistance to a variety of anticancer drugs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_provenance.
- NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_assertion evidence source_evidence_literature NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_provenance.
- NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_assertion SIO_000772 16685446 NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_provenance.
- NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_assertion wasDerivedFrom befree-20140225 NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_provenance.
- NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_assertion wasGeneratedBy ECO_0000203 NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_provenance.
- befree-20140225 importedOn "2014-02-25" NP514546.RAOBPGnT5cbZMTJ-uq_fjw2bXUKgm_B6-VbB4PmlCOSpE130_provenance.